TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

What is the clinical significance of secondary-AML-type mutations in de novo AML?

Featured:

Isolda FernandezIsolda Fernandez

Aug 6, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in AML


During the EHA 2022 Congress, the AML Hub spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, What is the clinical significance of secondary-AML-type mutations in de novo AML?

What is the clinical significance of secondary-AML-type mutations in de novo AML

Fernandez discusses the importance of the identification of AML mutations and the prognostic effects on patients (e.g., NPM1 and TP53 mutations). Fernandez outlines the incidence of mutations, and discusses a presentation from the EHA 2022 Congress about clinical and prognostic implications of secondary-AML-type mutations in de novo patients with AML.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content